Bioequivalence is the demonstration that two pharmaceutical products, such as a generic and a reference product, have no significant difference in the rate and extent to which the active ingredient reaches the systemic circulation under comparable conditions. It appears in generic-drug dossiers, pharmacokinetic study reports, and regulatory product information where substitution and interchangeability are assessed.
Translators encounter bioequivalence in generic drug submissions, clinical study protocols, pharmacokinetic reports, summary documents, and regulatory correspondence. It appears in tables of AUC and Cmax ratios, 90% confidence intervals, and statements about reference products, often in expert reports, patient information, and product labeling used for marketing authorization and interchangeability assessments.
A common mistake is translating bioequivalence as 'same effect' or 'therapeutic equivalence.' Bioequivalence is a pharmacokinetic comparison of rate and extent of absorption, not a direct clinical outcome claim. Using a broader term can overstate conclusions in regulatory dossiers or patient labeling and blur the distinction from clinical equivalence assessments.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →